Primary and Acquired Resistance to Targeted Treatment in BRAF V600E-mutated Metastatic Colorectal Cancer

计划入组 30 人 · 首次发布于 2026 年 6 月 1 日

Vemurafenib and Panitumumab Combination Therapy in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer

计划入组 16 人 · 首次发布于 2013 年 2 月 13 日

Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.

计划入组 25 人 · 首次发布于 2024 年 10 月 15 日

BRAF-V600E degrader

Oncolipin-IT Colorectal Cancer

Deflexifol

Austrian Breast & Colorectal Cancer Study Group

Austria

Cardiff Oncology

United States

BORDEAUX COLORECTAL INSTITUTE ACADEMY

France

Panitumumab Emerges as Viable Alternative to Cetuximab in BRAF-Mutated Colorectal Cancer Treatment

BREAKWATER Trial: Braftovi-Erbitux Plus Chemotherapy Shows Promise in BRAF V600E Metastatic Colorectal Cancer

FDA Approves New Therapies for Hemophilia, Colorectal Cancer, and Cystic Fibrosis